Advice
following an abbreviated submission:
bimatoprost 0.3mg/mL preservative-free eye drops (Lumigan UD®) are accepted for restricted use within NHS Scotland.
Indication under review: reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta-blockers).
SMC restriction: to use in patients who have proven sensitivity to the preservative benzalkonium chloride.
SMC has previously accepted preserved bimatoprost eye-drops for use in NHS Scotland. This preparation is substantially more expensive than the equivalent multi-dose eye drop preparation with preservative.
Download detailed advice80KB (PDF)
Medicine details
- Medicine name:
- bimatoprost 0.3mg/mL single-dose eye drops (Lumigan UD)
- SMC ID:
- 839/13
- Indication:
- Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta-blockers).
- Pharmaceutical company
- Allergan Ltd
- BNF chapter
- Eye
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 11 March 2013